Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Enlivex Therapeutics Ltd. (ENLV) had Free Cash Flow per Share of $-0.63 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-15.01M |
|
-- |
|
-- |
|
$15.89M |
|
$-15.89M |
|
$0.87M |
|
$-15.01M |
|
$-15.01M |
|
$-15.01M |
|
$-15.01M |
|
$-15.01M |
|
$-15.01M |
|
$-15.89M |
|
$-15.34M |
|
20.51M |
|
20.51M |
|
$-0.73 |
|
$-0.73 |
|
| Balance Sheet Financials | |
$25.99M |
|
$0.62M |
|
$1.69M |
|
$27.69M |
|
$3.80M |
|
-- |
|
$0.30M |
|
$4.10M |
|
$23.59M |
|
$23.59M |
|
$23.59M |
|
23.65M |
|
| Cash Flow Statement Financials | |
$-13.01M |
|
$9.06M |
|
$6.45M |
|
$1.23M |
|
$3.73M |
|
$2.50M |
|
$2.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.84 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.93M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-63.65% |
|
-63.65% |
|
-54.23% |
|
-63.65% |
|
$1.00 |
|
|
Free Cash Flow per Share |
$-0.63 |
$-0.63 |
|